Dr. Paul Wheatley-Price

Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.

Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.

Dr. Stephanie Snow

Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

Dr. Cheryl Ho

Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

Dr. Quincy Chu

Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).

Dr. Normand Blais

Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.